Antibodies
12 September 2024
Depemokimab late-breaking data presented at ERS show a 54% reduction in severe asthma exacerbations12 September 2024
Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU12 September 2024
IGI Announces Publication in Nature Cancer on ISB 2001, IGI’s Innovative Trispecific Antibody for Relapsed/Refractory Multiple Myeloma10 September 2024
AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs10 September 2024
Phanes Therapeutics Announces First Patient Dosed in Clinical Study of PT886 in Combination with Chemotherapy10 September 2024
Incendia Therapeutics Enrolls First Patient in Phase 1c Clinical Trial of PRTH-101, a Novel DDR1 Inhibitor6 September 2024
NextPoint Therapeutics Announces First-in-class T Cell Engager NPX372 As New Drug Candidate Targeting B7-H7 in Solid Tumors5 September 2024
Boehringer Ingelheim announces plans to advance potential new treatment for Geographic Atrophy, following positive Phase I results5 September 2024
BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 20244 September 2024
OncoC4 Announces First Patient Dosed in Phase 1 Trial for Novel SIGLEC10 Immune Checkpoint Inhibitor ONC-841 for Solid Tumors4 September 2024
Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular EdemaNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports